文献速递糖尿病

口服丁酸盐对长期1型糖尿病患者的先天免疫和胰岛自身免疫无影响:一项随机对照试验

Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial.
PubMed 文献 · Diabetologia · 2020-01-08

这项随机、双盲、交叉对照试验在30例长期1型糖尿病患者中比较了每日口服4克丁酸钠与安慰剂各1个月(中间洗脱1个月)的效果。丁酸盐治疗安全且显著影响粪便丁酸和丙酸水平,但未导致适应性免疫、先天免疫或其他任何结局变量的显著变化。结论认为口服丁酸盐补充对长期1型糖尿病患者的先天或适应性免疫无显著影响。

要点

  • 每日口服4克丁酸钠1个月在长期1型糖尿病患者中安全,并显著改变粪便短链脂肪酸水平。
  • 丁酸盐补充未引起单核细胞亚群、体外细胞因子产生等先天免疫指标的显著变化。
  • 胰岛自身免疫标志物、糖脂代谢、β细胞功能、肠道菌群等次要结局均无显著变化。

核心结论

  • 口服丁酸盐补充对长期1型糖尿病患者的先天或适应性免疫无显著影响。

研究设计与样本

  • 随机(1:1)、对照、双盲交叉试验,30例无合并症且未用药的长期1型糖尿病患者,每日口服4克丁酸钠或安慰剂各1个月,中间洗脱1个月。
  • 参与者按五例一组随机分配至先口服丁酸钠胶囊组或先口服安慰剂胶囊组,所有参与者、测量或检查人员及结局评估者均对分组设盲。
  • 数据在阿姆斯特丹大学医学中心收集。

主要发现

  • 全部30例参与者均纳入分析。
  • 粪便丁酸和丙酸水平受到口服丁酸盐补充的显著影响,且丁酸盐治疗安全。
  • 肠道短链脂肪酸的这种调节未导致适应性免疫或先天免疫的任何显著变化,也未导致其他任何结局变量的显著变化。

关键数值与推荐

  • 主要结局为先天免疫表型的变化(单核细胞亚群和体外细胞因子产生)。
  • 次要结局包括胰岛自身免疫血液标志物(细胞计数、淋巴细胞刺激指数和CD8量子点检测)、糖脂代谢、β细胞功能(混合餐试验)、肠道菌群和粪便短链脂肪酸的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The pathophysiology of type 1 diabetes has been linked to altered gut microbiota and more specifically to a shortage of intestinal production of the short-chain fatty acid (SCFA) butyrate, which may play key roles in maintaining intestinal epithelial integrity and in human and gut microbial metabolism. Butyrate supplementation can protect against autoimmune diabetes in mouse models. We thus set out to study the effect of oral butyrate vs placebo on glucose regulation and immune variables in human participants with longstanding type 1 diabetes. METHODS: We administered a daily oral dose of 4 g sodium butyrate or placebo for 1 month to 30 individuals with longstanding type 1 diabetes, without comorbidity or medication use, in a randomised (1:1), controlled, double-blind crossover trial, with a washout period of 1 month in between. Participants were randomly allocated to the 'oral sodium butyrate capsules first' or 'oral placebo capsules first' study arm in blocks of five. The clinical investigator received blinded medication from the clinical trial pharmacy. All participants, people doing measurements or examinations, or people assessing the outcomes were blinded to group assignment. The primary outcome was a change in the innate immune phenotype (monocyte subsets and in vitro cytokine production). Secondary outcomes were changes in blood markers of islet autoimmunity (cell counts, lymphocyte stimulation indices and CD8 quantum dot assays), glucose and lipid metabolism, beta cell function (by mixed-meal test), gut microbiota and faecal SCFA. The data was collected at the Amsterdam University Medical Centers. RESULTS: All 30 participants were analysed. Faecal butyrate and propionate levels were significantly affected by oral butyrate supplementation and butyrate treatment was safe. However, this modulation of intestinal SCFAs did not result in any significant changes in adaptive or innate immunity, or in any of the other outcome variables. In our discussion, we elaborate on this important discrepancy with previous animal work. CONCLUSIONS/INTERPRETATION: Oral butyrate supplementation does not significantly affect innate or adaptive immunity in humans with longstanding type 1 diabetes. TRIAL REGISTRATION: Netherlands Trial Register: NL4832 (www.trialregister.nl). DATA AVAILABILITY: Raw sequencing data are available in the European Nucleotide Archive repository (https://www.ebi.ac.uk/ena/browse) under study PRJEB30292. FUNDING: The study was funded by a Le Ducq consortium grant, a CVON grant, a personal ZONMW-VIDI grant and a Dutch Heart Foundation grant.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. de Groot PF, Nikolic T, Imangaliyev S, et al. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. Diabetologia. 2020. PMID: 31915895. doi:10.1007/s00125-019-05073-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。